Clinical Trials Logo

Behavioral Symptoms clinical trials

View clinical trials related to Behavioral Symptoms.

Filter by:

NCT ID: NCT00009217 Completed - Alzheimer's Disease Clinical Trials

Treatment of Behavioral Symptoms in Alzheimer's Disease

Start date: January 1999
Phase: Phase 4
Study type: Interventional

The optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear. The objective of this study is to evaluate the risk of relapse following discontinuation of haloperidol in patients with Alzheimer's disease (AD) with psychosis or agitation who respond to it. In Phase A of this study, AD outpatients with behavioral complications receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily, titrated individually to achieve the optimal trade-off between efficacy and side effects. Responders to Phase A participate in Phase B, a 24-week continuation trial in which patients are randomized to continuation haloperidol or placebo. The primary outcome is the time to relapse of psychosis or behavioral disturbance.